Project description
Harnessing artificial intelligence to predict genetic risk for common and rare diseases
Different people develop disease and respond to treatments differently. Moving away from the one-size-fits-all approach, personalised medicine pursues treatment options tailored to the genetic profile of individuals. The EU-funded INTERVENE project will develop next-generation tools for disease prevention, diagnosis and personalised treatment. INTERVENE will use powerful artificial intelligence technologies on a vast and diverse US-European pool of genomic and health data to calculate genetic risk scores that predict an individual’s susceptibility to a particular disease. The risk scores will be tested in clinical trials focusing on devastating common diseases, such as diabetes, cancer, and cardiovascular disease. INTERVENE will also develop and test the role of risk scores in several rare diseases as well as COVID-19 infection and severity.
Objective
The aim of INTERVENE is to develop and test next generation tools for disease prevention, diagnosis, and personalised treatment utilizing the first US-European pool of genomic and health data and integrating longitudinal and disease-relevant -omics data into genetic risk scores. Resulting in unprecedented potential for prediction, diagnosis, and personalised treatments for complex and rare diseases. Some of the largest biobanks in Europe and two in the USA will be securely linked and harmonized in a GDPR-compliant repository with data from more than 1.7 million genomes. INTERVENE will demonstrate the potential and benefits of powerful AI technologies on the next generation of integrative genetic scores (IGS). The clinical and economic benefits of IGS will be evaluated in key disease areas with major public health burden. Here, the newly developed IGS will be taken into clinical environment and their real-world benefits will be evaluated together with clinical experts, European patients advocate groups and medical societies and considering regulatory and ethical implications. Thus, a framework for legally and ethically responsible translation into wider clinical practice will be developed. Moreover, the partners will develop and test the role of IGS in several rare diseases as well as COVID-19 infection and severity. Importantly, to support the application of IGS via public-private partnerships including clinical practitioners, an AI-enabled federated data analysis platform, the ‘IGS4EU’ platform, will be developed for automated IGS generation and interpretation for end-users. Additionally, the IGS4EU platform will allow access of the INTERVENE data and the methodology know-how to the AI community through a competition-based benchmarking environment. In the long term, the IGS4EU platform aims to grow the disease coverage and enable a wide adoption of IGS as a gold standard in clinical research and practice.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
00014 HELSINGIN YLIOPISTO
Finland